DMD and Duchenne muscular dystrophy: The implantation of autologous, genetically corrected myogenic cells is a widely explored strategy to introduce functional dystrophin expression in vivo that can persist for years following transplantation.42 Here, we demonstrate that a clonally derived, genetically corrected population of DMD patient cells can generate human dystrophin expression in vivo that is properly localized to the sarcolemma membrane.